Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2014 Filed Mar 5, 2014 22:36 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 1,700 | $32.66 | $55,522.00 |
DisclosureSEC source: 0001225208-14-007555 · doc4.xml · nonDerivative · entry 3 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,422 Read SEC document |
| March 04, 2014 Filed Mar 5, 2014 22:36 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 1,600 | $32.65 | $52,240.00 |
DisclosureSEC source: 0001225208-14-007555 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,122 Read SEC document |
| March 04, 2014 Filed Mar 5, 2014 22:36 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 500 | $32.67 | $16,335.00 |
DisclosureSEC source: 0001225208-14-007555 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,722 Read SEC document |
| March 04, 2014 Filed Mar 5, 2014 22:36 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 28,089 | $32.58 | $915,139.62 |
DisclosureSEC source: 0001225208-14-007556 · doc4.xml · nonDerivative · entry 2 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,571 Read SEC document |
| March 04, 2014 Filed Mar 5, 2014 22:36 UTC |
Dolsten MikaelPresident R&D
|
SaleCommon Stock | 7,700 | $32.57 | $250,789.00 |
DisclosureSEC source: 0001225208-14-007556 · doc4.xml · nonDerivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,660 Read SEC document |
| March 04, 2014 Filed Mar 5, 2014 22:37 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
SaleCommon Stock | 5,082 | $32.55 | $165,419.10 |
DisclosureSEC source: 0001225208-14-007557 · doc4.xml · nonDerivative · entry 13 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,756 Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 22:37 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
OtherPhantom Stock Units SSP · Derivative | 11,877 | $31.98 | $379,826.46 |
DisclosureSEC source: 0001225208-14-007557 · doc4.xml · derivative · entry 16 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,877 shares Expires not disclosed F3 · derivative.exercise_price: Each unit represents one phantom share of common stock. F4 · shares: This transaction constitutes an intra-plan transfer involving the Pfizer stock unit fund under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. F5 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F5 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 22:37 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 75,500 | $0.00 Strike: $26.20 | $0.00 |
DisclosureSEC source: 0001225208-14-007557 · doc4.xml · derivative · entry 15 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,500 shares Expires 2015-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options are fully exercisable. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 22:37 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
OtherCommon Stock | 6,695 | $31.98 | $214,106.10 |
DisclosureSEC source: 0001225208-14-007557 · doc4.xml · nonDerivative · entry 14 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Indirect · By Rule 16b-3 Plan Disclosed balance after: 0 F1 · shares: This transaction constitutes an intra-plan transfer involving the Pfizer stock fund under the Company's Qualified Savings Plan. Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 22:37 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
SaleCommon Stock | 24,900 | $32.02 | $797,298.00 |
DisclosureSEC source: 0001225208-14-007557 · doc4.xml · nonDerivative · entry 12 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,838 Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 22:37 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
SaleCommon Stock | 18,200 | $32.00 | $582,400.00 |
DisclosureSEC source: 0001225208-14-007557 · doc4.xml · nonDerivative · entry 11 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,738 Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 22:37 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
SaleCommon Stock | 14,425 | $32.01 | $461,744.25 |
DisclosureSEC source: 0001225208-14-007557 · doc4.xml · nonDerivative · entry 10 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,938 Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 22:37 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
SaleCommon Stock | 10,261 | $32.06 | $328,967.66 |
DisclosureSEC source: 0001225208-14-007557 · doc4.xml · nonDerivative · entry 9 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,363 Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 22:37 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
SaleCommon Stock | 7,500 | $32.07 | $240,525.00 |
DisclosureSEC source: 0001225208-14-007557 · doc4.xml · nonDerivative · entry 8 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,624 Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 22:37 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
SaleCommon Stock | 6,800 | $31.99 | $217,532.00 |
DisclosureSEC source: 0001225208-14-007557 · doc4.xml · nonDerivative · entry 7 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,124 Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 22:37 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
SaleCommon Stock | 6,100 | $31.98 | $195,078.00 |
DisclosureSEC source: 0001225208-14-007557 · doc4.xml · nonDerivative · entry 6 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,924 Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 22:37 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
SaleCommon Stock | 4,600 | $32.08 | $147,568.00 |
DisclosureSEC source: 0001225208-14-007557 · doc4.xml · nonDerivative · entry 5 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,024 Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 22:37 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
SaleCommon Stock | 3,100 | $32.04 | $99,324.00 |
DisclosureSEC source: 0001225208-14-007557 · doc4.xml · nonDerivative · entry 4 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,624 Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 22:37 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
SaleCommon Stock | 1,600 | $32.03 | $51,248.00 |
DisclosureSEC source: 0001225208-14-007557 · doc4.xml · nonDerivative · entry 3 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,724 Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 22:37 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
SaleCommon Stock | 375 | $31.97 | $11,988.75 |
DisclosureSEC source: 0001225208-14-007557 · doc4.xml · nonDerivative · entry 2 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,324 Read SEC document |
| March 03, 2014 Filed Mar 5, 2014 22:37 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Exercise / conversionCommon Stock | 75,500 | $26.20 | $1,978,100.00 |
DisclosureSEC source: 0001225208-14-007557 · doc4.xml · nonDerivative · entry 1 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2014 Filed Mar 4, 2014 14:06 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 106 | $32.11 | $3,403.66 |
DisclosureSEC source: 0001225208-14-007148 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,882 Underlying: Common Stock · 106 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
BOURLA ALBERTGroup President
|
GrantStock Appreciation Rights · Derivative | 51,230 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-14-006885 · doc4.xml · derivative · entry 9 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,230 Underlying: Common Stock · 51,230 shares Expires 2021-02-27 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
BOURLA ALBERTGroup President
|
GrantStock Appreciation Rights · Derivative | 64,322 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-14-006885 · doc4.xml · derivative · entry 8 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,322 Underlying: Common Stock · 64,322 shares Expires 2019-02-27 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
BOURLA ALBERTGroup President
|
GrantCommon Stock | 11,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-006885 · doc4.xml · nonDerivative · entry 5 BOURLA ALBERT · CIK 0001595703 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,393 F5 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantStock Appreciation Rights · Derivative | 20,492 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-14-006886 · doc4.xml · derivative · entry 9 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,492 Underlying: Common Stock · 20,492 shares Expires 2021-02-27 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantStock Appreciation Rights · Derivative | 25,729 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-14-006886 · doc4.xml · derivative · entry 8 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,729 Underlying: Common Stock · 25,729 shares Expires 2019-02-27 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantCommon Stock | 4,689 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-006886 · doc4.xml · nonDerivative · entry 5 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,199 F5 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 145,150 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-14-006887 · doc4.xml · derivative · entry 9 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,150 Underlying: Common Stock · 145,150 shares Expires 2021-02-27 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 182,247 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-14-006887 · doc4.xml · derivative · entry 8 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,247 Underlying: Common Stock · 182,247 shares Expires 2019-02-27 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantCommon Stock | 33,214 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-006887 · doc4.xml · nonDerivative · entry 5 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433,913 F5 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 126,366 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-14-006888 · doc4.xml · derivative · entry 6 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,366 Underlying: Common Stock · 126,366 shares Expires 2021-02-27 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 158,662 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-14-006888 · doc4.xml · derivative · entry 5 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,662 Underlying: Common Stock · 158,662 shares Expires 2019-02-27 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
Dolsten MikaelPresident R&D
|
GrantCommon Stock | 28,915 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-006888 · doc4.xml · nonDerivative · entry 3 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,360 F3 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
Germano Geno JGroup President
|
GrantStock Appreciation Rights · Derivative | 122,951 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-14-006889 · doc4.xml · derivative · entry 7 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,951 Underlying: Common Stock · 122,951 shares Expires 2021-02-27 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
Germano Geno JGroup President
|
GrantStock Appreciation Rights · Derivative | 154,374 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-14-006889 · doc4.xml · derivative · entry 6 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,374 Underlying: Common Stock · 154,374 shares Expires 2019-02-27 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
Germano Geno JGroup President
|
GrantCommon Stock | 28,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-006889 · doc4.xml · nonDerivative · entry 3 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,834 F3 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
HILL CHARLES HExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 66,428 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-14-006890 · doc4.xml · derivative · entry 9 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,428 Underlying: Common Stock · 66,428 shares Expires 2021-02-27 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
HILL CHARLES HExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 83,405 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-14-006890 · doc4.xml · derivative · entry 8 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,405 Underlying: Common Stock · 83,405 shares Expires 2019-02-27 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
HILL CHARLES HExecutive Vice President
|
GrantCommon Stock | 15,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-006890 · doc4.xml · nonDerivative · entry 5 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,264 F5 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 51,230 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-14-006891 · doc4.xml · derivative · entry 9 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,230 Underlying: Common Stock · 51,230 shares Expires 2021-02-27 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 64,322 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-14-006891 · doc4.xml · derivative · entry 8 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,322 Underlying: Common Stock · 64,322 shares Expires 2019-02-27 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantCommon Stock | 11,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-006891 · doc4.xml · nonDerivative · entry 5 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,623 F5 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 23,907 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-14-006892 · doc4.xml · derivative · entry 9 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,907 Underlying: Common Stock · 23,907 shares Expires 2021-02-27 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 30,017 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-14-006892 · doc4.xml · derivative · entry 8 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,017 Underlying: Common Stock · 30,017 shares Expires 2019-02-27 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantCommon Stock | 5,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-006892 · doc4.xml · nonDerivative · entry 5 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,327 F5 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
Lewis-Hall Freda CExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 64,891 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-14-006893 · doc4.xml · derivative · entry 6 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,891 Underlying: Common Stock · 64,891 shares Expires 2021-02-27 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
Lewis-Hall Freda CExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 81,475 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-14-006893 · doc4.xml · derivative · entry 5 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,475 Underlying: Common Stock · 81,475 shares Expires 2019-02-27 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
Lewis-Hall Freda CExecutive Vice President
|
GrantCommon Stock | 14,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-006893 · doc4.xml · nonDerivative · entry 3 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,886 F3 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 27, 2014 Filed Feb 28, 2014 21:52 UTC |
MADDALUNA ANTHONY JExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 49,522 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-14-006894 · doc4.xml · derivative · entry 9 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,522 Underlying: Common Stock · 49,522 shares Expires 2021-02-27 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.